Literature DB >> 26286198

Prognostic Significance of Sarcomatous Change in Patients with Hepatocellular Carcinoma After Surgical Resection.

Jiong Lu1, Xian-Ze Xiong1, Fu-Yu Li1, Hui Ye1, Yi-Xin Lin1, Rong-Xing Zhou1, Yu-Long Cai1, Yan-Wen Jin1, Nan-Sheng Cheng2.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) with sarcomatous change (SC) is a rare malignancy associated with high aggressiveness and poor prognosis; however, its prognostic significance remains unclear.
METHODS: From January 1994 to April 2012, surgically resected HCCs with SC (n = 52) at West China Hospital were retrospectively reviewed. HCC with SC was defined as the concomitant presence of the sarcomatous component occupying at least 10 % (but not predominantly) of the HCC-bearing tissue. To validate its prognostic significance, we compared the clinicopathological features and survival rates of these patients with a cohort of 214 randomly selected ordinary HCC patients during the same period.
RESULTS: The clinicopathological characteristics of HCC with SC were similar to those of ordinary HCC, with the exception of capsule formation, adjacent organ invasion, lymph node metastasis, and TNM staging. A total of 45 (86.5 %) HCC patients with SC experienced a recurrence, with a median time to recurrence of 6.0 months. Overall survival (OS) rates in the sarcomatous HCC group at 1, 2, and 3 years were 55.8, 25, and 17.3 %, respectively, which were significantly lower than those in the ordinary HCC group (p < 0.001). On multivariable analysis, macrovascular invasion, satellite nodules, and R1/R2 resection were identified as independent risk factors for shorter disease-free survival and OS.
CONCLUSIONS: The presence of SC in HCC was uncommon, and was associated with much poorer prognosis than ordinary HCC. Radical resection with negative margin is essential for improving the prognosis. Future prospective studies are warranted to determine if recurrent patients can benefit from postoperative adjuvant therapies.

Entities:  

Mesh:

Year:  2015        PMID: 26286198     DOI: 10.1245/s10434-015-4818-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

Review 1.  Sarcomatoid hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Tian-Run Lv; Hai-Jie Hu; Parbatraj Regmi; Fei Liu; Fu-Yu Li
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-24       Impact factor: 4.553

2.  Characterization of a new murine cell line of sarcomatoid hepatocellular carcinoma and its application for biomarker/therapy development.

Authors:  Chia-Hung Yen; Chih-Chung Lai; Chen-Chung Liao; Sheng-Fan Wang; Yi-Jen Liao; Chien-Yi Tung; Jung-Hsien Hung; Shiu-Feng Huang; Yi-Ming Arthur Chen
Journal:  Sci Rep       Date:  2017-06-08       Impact factor: 4.379

3.  Imaging and clinical features of primary hepatic sarcomatous carcinoma.

Authors:  Dongli Shi; Liang Ma; Dawei Zhao; Jing Chang; Chen Shao; Shi Qi; Feng Chen; Yunfang Li; Xing Wang; Yanyan Zhang; Jing Zhao; Hongjun Li
Journal:  Cancer Imaging       Date:  2018-10-12       Impact factor: 3.909

4.  Clinical and imaging characteristics of primary hepatic sarcomatoid carcinoma and sarcoma: a comparative study.

Authors:  Dongli Shi; Jun Sun; Liang Ma; Jing Chang; Hongjun Li
Journal:  BMC Cancer       Date:  2020-10-09       Impact factor: 4.430

Review 5.  A retrospective study on the clinical and pathological features of hepatic sarcomatoid carcinoma: Fourteen cases of a rare tumor.

Authors:  Shuoshuo Ma; Chunshuang Li; Yang Ma; Xiaolei Wang; Dengyong Zhang; Zheng Lu
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

6.  Clinicopathological characteristics and surgical outcomes of sarcomatoid hepatocellular carcinoma.

Authors:  Jian-Ping Wang; Zhi-Gang Yao; Ya-Wen Sun; Xi-Han Liu; Feng-Kai Sun; Cun-Hu Lin; Fu-Xin Ren; Bei-Bei Lv; Shuai-Jun Zhang; Yang Wang; Fan-Ying Meng; Shun-Zhen Zheng; Wei Gong; Jun Liu
Journal:  World J Gastroenterol       Date:  2020-08-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.